A Phase III Clinical Trial of Hydroxyflutamide (Liproca Depot) in localized Prostate Cancer within the intermediate risk group

Status: Suspended

Phase of Trial: Phase III

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Nov 2024 According to a LIDDS media release, the company has received guidance from the EMA, and the company's aim is out-licensing Liproca depot to a company which can implement a clinical phase 3 program, with a launch in major markets.
22 Feb 2024 Status changed to suspended, according to a LIDDS media release.
22 Feb 2024 According to a LIDDS media release, company decided to halt all clinical development in order to significantly strengthen the company's financial sustainability as additional funding was not considered possible to obtain in the weak market environment. The measures will have full effect from the beginning of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com